Simon Farrell

SEC source: 0001965585-26-000006 · wk-form4_1784847165.xml · derivative · entry 1

Simon Farrell · CIK 0001965585 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,500

Underlying: Common Stock · 30,500 shares

Expires 2036-07-22

F1 · derivative.exercise_date: The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

SEC source: 0001193125-26-061385 · ownership.xml · derivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2036-02-18

F1 · derivative.exercise_date: This option was granted on February 19, 2026. The 160,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

SEC source: 0000950170-25-080885 · ownership.xml · derivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,400

Underlying: Common Stock · 72,000 shares

Expires 2034-02-14

F1 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 72,000 shares of common stock.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 9

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Stock · 31,250 shares

Expires 2032-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 8

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,187

Underlying: Common Stock · 63,813 shares

Expires 2030-09-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: This option was granted on September 22, 2020. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on September 22, 2021 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through September 22, 2024.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 7

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires 2031-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 17,500 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis.

SEC source: 0000950170-25-037880 · ownership.xml · derivative · entry 6

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,400

Underlying: Common Stock · 38,400 shares

Expires 2034-02-14

F5 · shares: Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 120,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 38,400 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 5

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,900

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.14 to $7.16 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 4

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,250

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.14 to $7.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 3

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,213

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 2

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,963

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

SEC source: 0000950170-25-037880 · ownership.xml · nonDerivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This exercise of stock options was effected pursuant to a Rule 10b5-1 trading plan that was adopted on April 9, 2024.

SEC source: 0000950170-25-024114 · ownership.xml · derivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,500

Underlying: Common Stock · 225,500 shares

Expires 2035-02-17

F1 · derivative.exercise_date: This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.

SEC source: 0000950170-24-016465 · ownership.xml · derivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2034-02-14

F1 · derivative.exercise_date: This option was granted on February 15, 2024. The 175,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028.

SEC source: 0001209191-23-038744 · doc4.xml · derivative · entry 2

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 6,250 shares

Expires 2032-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0001209191-23-038744 · doc4.xml · nonDerivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,650

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-017148 · doc4.xml · derivative · entry 2

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,250

Underlying: Common Stock · 18,750 shares

Expires 2032-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option was granted on February 11, 2022. The 75,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026.

SEC source: 0001209191-23-017148 · doc4.xml · nonDerivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-010190 · doc4.xml · derivative · entry 1

Simon Farrell · CIK 0001965585 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2033-02-15

F1 · derivative.exercise_date: This option was granted on February 16, 2023. The 100,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027.